NCT03801278No Longer Available不适用
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
详细描述
This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That study is closing and this expanded access protocol allows this single patient to continue receiving this agent.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Understand and sign an Institutional Review Board-approved informed consent form prior to receiving bemarituzumab
- •Previously enrolled on the FPA144-001 study, received bemarituzumab and obtained clinical benefit from the investigational product (IP) administration
排除标准
- •Pregnancy and lactation
研究者
相似试验
终止
1 期
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionSolid TumorsNCT05325866Amgen260
已完成
2 期
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01868893Genentech, Inc.20
尚未招募
2 期
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryHigh Grade Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian-tube CancerOvarian CancerNCT06063070Sun Yat-sen University44
Approved For Marketing
不适用
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseGraves' OrbitopathyThyroid Eye DiseaseNCT04040894Amgen
已完成
3 期
Bintrafusp Alfa Program Rollover StudyCancerLung CancerNCT05061823EMD Serono Research & Development Institute, Inc.22